Emerging studies suggest this peptide, a dual stimulator targeting both GLP-1 and GIP , could provide a notable advancement for obesity treatment. Early human trials have indicated substantial losses in abdominal mass , possibly outperforming other weight-loss therapies . However , more assessment is required to fully determine its sustained effica